Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Ragini R. Kudchadkar"'
Autor:
Michael A. Postow, Peter A. Forsyth, Hussein Abdul-Hassan Tawbi, Igor Puzanov, Ahmad A. Tarhini, Jasmine I. Rizzo, Alain Algazi, F. Stephen Hodi, Omid Hamid, Anna C. Pavlick, Sekwon Jang, Ragini R. Kudchadkar, Christopher D. Lao, Karl D. Lewis, David A. Reardon, Nikhil I. Khushalani, Stergios J. Moschos, Kim Margolin, John A. Glaspy, Reena Thomas, Anne Sumbul, Michael B. Atkins, M. S. Ernstoff
Publikováno v:
Neuro-Oncology
Neuro Oncol
Neuro-oncology, vol 23, iss 11
Neuro Oncol
Neuro-oncology, vol 23, iss 11
Background In patients with melanoma and asymptomatic brain metastases (MBM), nivolumab plus ipilimumab provided an intracranial response rate of 55%. Here, we present the first report for patients who were symptomatic and/or required corticosteroids
Autor:
Marvi Tariq, Constance Harrell Shreckengost, Chao Zhang, Michael C. Lowe, Clara R. Farley, Ragini R. Kudchadkar, Keith A. Delman
Publikováno v:
Annals of Surgical Oncology. 28:6140-6151
The impact of obesity on early-stage melanoma is poorly understood. We examined the impact of overweight and obesity on clinical outcomes in locoregional melanoma. Adults who underwent surgery at Emory University Healthcare between 2010 and 2017 for
Autor:
Chrystal M. Paulos, Jessica M Keilson, Hannah M. Knochelmann, Michael C. Lowe, Ragini R. Kudchadkar
Publikováno v:
J Surg Oncol
While surgical resection, local and cytotoxic therapies have long formed the basis of cancer care, immunotherapy now plays a key role in supplementing and even replacing these agents in the first line. Here we review the early success of programmed c
Autor:
Brian R. Gastman, Ahmad A. Tarhini, Robert M. Conry, Pauline Funchain, Karl D. Lewis, Antoni Ribas, Sapna Pradyuman Patel, Hongli Li, Kenneth F. Grossmann, Magdalena Kovacsovics-Bankowski, Teresa M. Petrella, Elizabeth I. Buchbinder, Nageatte Ibrahim, Ragini R. Kudchadkar, James Moon, Douglas B. Johnson, Thach-Giao Truong, Larissa A. Korde, Michael V. Knopp, Kari Kendra, Elad Sharon, Scot Ebbinghaus, Bartosz Chmielowski, Vernon K. Sondak, John M. Kirkwood, Zeynep Eroglu, Nikhil I. Khushalani, Justine V. Cohen, Megan Othus, Krishna S Gunturu, Sama Ahsan
Publikováno v:
Cancer discovery, vol 12, iss 3
Cancer Discov
Cancer Discov
We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFNα-2b for one year or ipilimumab for up
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be95c3ea01eedee0bb4c9a85fc5d89b2
https://escholarship.org/uc/item/8x51z8rb
https://escholarship.org/uc/item/8x51z8rb
Autor:
Ragini R. Kudchadkar, John A. Thompson, Wim van Dijck, Michael Smylie, David Hogg, Kevin B. Kim, Maurice Lobo, Gregory A. Daniels, Anna C. Pavlick, Mario Sznol, David R. Spigel, Scott Ernst, Rene Gonzalez, Nikhil I. Khushalani, Christopher D. Lao, F. Stephen Hodi, Paul B. Chapman, William H. Sharfman, Michael B. Atkins, Jose Gerard Monzon
Publikováno v:
Melanoma Research
Supplemental Digital Content is available in the text.
CheckMate 218, a North American expanded access program (EAP), investigated nivolumab plus ipilimumab in patients with advanced melanoma. Safety and efficacy, including 2-year survival in cl
CheckMate 218, a North American expanded access program (EAP), investigated nivolumab plus ipilimumab in patients with advanced melanoma. Safety and efficacy, including 2-year survival in cl
Autor:
Vanna Chiarion-Sileni, Pablo Luis Ortiz Romero, Daniil Stroyakovskiy, Rosalie Fisher, Alexander M.M. Eggermont, James Larkin, Paul Lorigan, Axel Hauschild, Micaela Hernberg, Mario Mandalà, Alexander J C van Akkooi, Michal Kicinski, Susana Puig, Nageatte Ibrahim, Lars Bastholt, Victoria Atkinson, Peter Hersey, Pietro Quaglino, Shahneen Sandhu, Christian U. Blank, Georgina V. Long, Anna Maria Di Giacomo, Andrey Meshcheryakov, Naoya Yamazaki, Stefan Suciu, Sandrine Marreaud, Peter Mohr, Ragini R. Kudchadkar, Inge Marie Svane, Matthew Strother, Clemens Krepler, Caroline Robert, Paola Queirolo, Catherine Barrow
Publikováno v:
Eggermont, A MM, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Ortiz Romero, P L, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A CJ, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European Journal of Cancer, vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023
Eggermont, A M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Ortiz Romero, P L, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European journal of cancer (Oxford, England : 1990), vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023
Eggermont, A M M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Romero, P L O, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European Journal of Cancer, vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023
Eggermont, A M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Ortiz Romero, P L, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European journal of cancer (Oxford, England : 1990), vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023
Eggermont, A M M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Romero, P L O, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European Journal of Cancer, vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023
Background: In the phase III double-blind European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 trial, pembrolizumab improved recurrence free and distant metastasis-free survival in patients with stage III cutaneous melanoma wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::206bf54251ce7ab0bcaf3dc33467c927
https://findresearcher.sdu.dk:8443/ws/files/194774299/PIIS0959804921006201.pdf
https://findresearcher.sdu.dk:8443/ws/files/194774299/PIIS0959804921006201.pdf
Autor:
Michael C. Lowe, Ragini R. Kudchadkar
Publikováno v:
Surgical Oncology Clinics of North America. 29:445-453
With the universal adoption of immune checkpoint blockade and agents targeting BRAF-mutated melanomas in the metastatic setting, numerous clinical trials have evaluated these agents in the neoadjuvant setting. These smaller trials have shown promisin
Autor:
Mohammad K. Khan, Cecilia Jiang, David G. Wallington, Melinda L. Yushak, Ragini R. Kudchadkar, David H. Lawson, Ahmad A Tarhini, Christopher J. Anker
Publikováno v:
Neurosurgery. 87:498-515
Over 90 000 people are expected to be diagnosed with melanoma in the United States this year. The development of brain metastases is particularly difficult to manage. Over the past few years, melanoma patients with multiple unresectable brain metasta
Autor:
Ruth Plummer, Ralf Gutzmer, Anne Lynn S. Chang, John T. Lear, Martin Kaatz, Uwe Trefzer, Alexandros Stratigos, Carmen Loquai, Luc Dirix, Patrick Combemale, Nicholas Squittieri, Karl D. Lewis, Reinhard Dummer, Michael R. Migden, A Guminksi, Ragini R. Kudchadkar, H.-J. Schulze
Publikováno v:
British Journal of Dermatology. 182:1369-1378
Background: Basal cell carcinomas (BCCs) exhibit aberrant activation of the hedgehog pathway. Sonidegib is a hedgehog pathway inhibitor approved for the treatment of locally advanced BCC (laBCC) and metastatic BCC (mBCC) based on primary results of t
Autor:
David H. Lawson, Haydn T. Kissick, R. Donald Harvey, Jacqueline T. Brown, Colleen Lewis, Olatunji B. Alese, Ragini R. Kudchadkar, Bassel F. El-Rayes, Mehmet Asim Bilen, Walid L. Shaib, Christina Wu, Amir Ishaq Khan, Yuan Liu, Julie M. Shabto, Hannah Collins, Rathi N. Pillai, Suresh S. Ramalingam, Milton Williams, Alexandra Speak, Viraj A. Master, Dylan J. Martini, Conor E. Steuer, Bradley C. Carthon, Mehmet Akce, Taofeek K. Owonikoko
Publikováno v:
The Oncologist
Oncologist
Oncologist
Background Sarcopenia and inflammation have been associated with poor survival in patients with cancer. We explored the combined effects of these variables on survival in patients with cancer treated with immunotherapy. Methods We performed a retrosp